Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GDC-1261 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Dose Escalation + Expansion | EXPERIMENTAL | Participants will receive GDC-1261 as per the schedule described in the protocol. |
| Name | Type | Description |
|---|---|---|
| GDC-1261 | DRUG | Participants will receive GDC-1261 as per the schedule described in the protocol. |
Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) Performance Status of \<=1 * Life expectancy is \>= 3 months * Histologically or cytologically confirmed prostate adenocarcinoma * Disease progression during or following the direct prior line of therapy * Ongoing androgen deprivation ...
Top 20 of 53 competitors
GDC-1261 is an investigational small molecule being studied for the treatment of advanced or metastatic prostate cancer. It is currently in Phase 1 clinical development, with a trial evaluating its safety, pharmacokinetics, and preliminary activity in participants with advanced or metastatic prostate cancer.
GDC-1261 is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company is conducting a Phase 1 clinical trial of the drug in participants with advanced or metastatic prostate cancer.
GDC-1261 is in Phase 1 clinical development. It is an investigational drug, not yet approved by regulatory authorities, and is being evaluated in a Phase 1 study for advanced or metastatic prostate cancer.
GDC-1261 is being studied in a single Phase 1 clinical trial with the identifier NCT07567846. The trial is recruiting participants with advanced or metastatic prostate cancer and is being conducted in the United States, Australia, and the United Kingdom.
No alternative names for GDC-1261 have been disclosed. The drug is identified solely as GDC-1261 in its clinical trial documentation.